Objective To explore the clinical effect of Naoxintong Capsules combined with Dihydroergotoxine Methanesulfonate Sustained Release Tablets in treatment of recovery period of cerebral infarction. Methods Patients (84 cases) with recovery period of cerebral infarction in Northern Jiangsu People’s Hospital from January 2022 to December 2022 were randomly divided into control (42 cases) and treatment (42 cases) group. Patients in the control group were po administered with Dihydroergotoxine Methanesulfonate Sustained Release Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Naoxintong Capsules on the basis of the control group, 3 grains/time, three times daily. All patients were treated for 30 d. The clinical evaluations, symptom relief time, the scores of ADL, NIHSS and FMA in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was 95.24%, which was significantly higher than 80.95% of the control group ( P < 0.05). After treatment, the time of symptom relief in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, NIHSS score in two groups was significantly decreased, while ADL and FMA scores were significantly increased (P < 0.05), and the scores in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The combined treatment of Dihydroergotoxine Methanesulfonate Sustained Release Tablets and Naoxintong Capsules can effectively relieve the symptoms, obviously restore the brain nerve defect and improve the ability of daily activity.

R971

國家衛(wèi)生健康委腦卒中防治工程委員會項目（GN-2018R0010）